Evidence map›Paper›PMID 30814649›Full record

ReviewNature reviews. Molecular cell biology2019

Identification of bioactive metabolites using activity metabolomics.

Markus M Rinschen, Julijana Ivanisevic, Martin Giera, Gary Siuzdak

Registry-linked trialAbstract readReview
In one paragraph

Review in Nature reviews. Molecular cell biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05834426 (Omic Technologies Applied to the Study of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers), which is not on this map. Cited by 510 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
510citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05834426 not yet recruitingnot on this mapstarted 2023, after this paper: background citation

Omic Technologies Applied to the Study of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

TypeobservationalSponsorSociedad de Lucha Contra el Cáncer del EcuadorRan2023 to 2026Enrolled50ConditionsLymphoma, B-Cell, Neoplasms, Cancer, High-grade B-cell LymphomaArmsPlasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
3 · Its place in the literature

Who cites it

510 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. The chemical blueprint of Trichoderma for next-generation microbial biostimulants.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Seasonal PMToxics · 2026
    Article
  17. MSTNCells · 2026
    Article
  18. Transcriptomics and metabolomics reveal the protective effect of β-hydroxybutyrate on sepsis associated encephalopathy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  19. Article
  20. Article

450 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Markus M RinschenThe Scripps Research Institute, Center for Metabolomics and Mass Spectrometry, La Jolla, CA, USA.
Julijana IvanisevicMetabolomics Platform, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-8267-2705
Martin GieraLeiden University Medical Center, Center for Proteomics & Metabolomics, Leiden, Netherlands. M.A.Giera@lumc.nl.ORCID http://orcid.org/0000-0003-1684-1894
Gary SiuzdakThe Scripps Research Institute, Center for Metabolomics and Mass Spectrometry, La Jolla, CA, USA. Siuzdak@scripps.edu.ORCID http://orcid.org/0000-0002-4749-0014

Funding

Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2000 to 2021
$37.7M
Pharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ALNOUTI, YAZEN · 2010 to 2019
$16.8M
Metabolomics Technologies to Advance Biomedical ResearchR35GM130385 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI GARY E SIUZDAK · 2019 to 2026
$3.9M
Mummichog 3, aligning mass spectrometry data to biological networks - Neutral LossU01CA235493 · NCI · JACKSON LABORATORY · PI LI, SHUZHAO, SIUZDAK, GARY E · 2018 to 2021
$2.0M
XCMS Metabolomic Data TechnologyR01GM114368 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI SIUZDAK, GARY E · 2015 to 2018
$1.5M
NCI NIH HHS U01 CA235493NIDA NIH HHS P01 DA028555NIGMS NIH HHS R01 GM114368NIGMS NIH HHS R35 GM130385NIMH NIH HHS P30 MH062261
6 · The paper itself

Abstract

The metabolome, the collection of small-molecule chemical entities involved in metabolism, has traditionally been studied with the aim of identifying biomarkers in the diagnosis and prediction of disease. However, the value of metabolome analysis (metabolomics) has been redefined from a simple biomarker identification tool to a technology for the discovery of active drivers of biological processes. It is now clear that the metabolome affects cellular physiology through modulation of other 'omics' levels, including the genome, epigenome, transcriptome and proteome. In this Review, we focus on recent progress in using metabolomics to understand how the metabolome influences other omics and, by extension, to reveal the active role of metabolites in physiology and disease. This concept of utilizing metabolomics to perform activity screens to identify biologically active metabolites - which we term activity metabolomics - is already having a broad impact on biology.

Indexed as

MetabolomeMetabolomicsAnimalsBiomarkersHumansBiomarkers

Identifiers

PMID30814649
PMCPMC6613555

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.